A 60-Year-Old Man With Early Relapse/Refractory Multiple Myeloma
Aimee Merino, MD, discusses the management of a 60-year-old patient with early relapse/refractory multiple myeloma and highlights the importance of identifying high-risk disease, the referral process for chimeric antigen receptor T-cell therapy, and the latest efficacy outcomes from the CARTITUDE-4 trial while also addressing emerging treatment strategies and challenges in managing relapsed/refractory multiple myeloma.
EP. 1: A 60-Year-Old Man With Early Relapse Multiple Myeloma
December 20th 2024Aimee Merino, MD, discusses how the treatment decision for a 60-year-old patient with early relapse/refractory multiple myeloma, involving chimeric antigen receptor (CAR) T-cell therapy, aligns with the goals of therapy while exploring alternative treatment options and considerations for high-risk patients.
Watch
EP. 2: Identification, Evaluation, and Management of High-Risk Disease in Early R/R MM
January 2nd 2025Aimee Merino, MD, discusses how the identification, evaluation, and management of high-risk disease in early relapsed/refractory multiple myeloma (R/R MM) involves prioritizing specific risk factors, distinguishing functional high-risk patients from those with standard risk, and tailoring treatment strategies accordingly.
Watch
